These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39078779)

  • 1. Ceftazidime-avibactam resistance determination in carbapenem-resistant Klebsiella pneumoniae infections before its use in practice.
    Eren-Kutsoylu OÖ; Ceylan-Çimendağ H; Sari-Kaygisiz AN; Tanriverdi ES; Özbek ÖA; Öktem IMA; Otlu B; Avkan-Oğuz V
    J Infect Dev Ctries; 2024 Jul; 18(7):1020-1025. PubMed ID: 39078779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae: A phenotypic and genotypic analysis.
    Krithika VM; Ganesan V; Rajendran T
    Indian J Med Microbiol; 2024; 49():100603. PubMed ID: 38705276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of a Stable and Transferable
    Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
    Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Expression and Amplification of
    Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X
    Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of
    Won EJ; Park K; Jeong YS; Kim J; Choi Y; Kim SH; Kim MN; Sung H
    J Korean Med Sci; 2024 Jul; 39(25):e208. PubMed ID: 38952349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
    Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
    Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
    Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S; Er DK; Dündar D; Keçeli SA
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
    Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
    J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.
    Castón JJ; Gallo M; García M; Cano A; Escribano A; Machuca I; Gracia-Aufinger I; Guzman-Puche J; Pérez-Nadales E; Recio M; Muñoz M; Martínez-Martínez L; Torre-Cisneros J;
    Int J Antimicrob Agents; 2020 Sep; 56(3):106075. PubMed ID: 32629116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.
    Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A
    Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM; Antochevis LC; Magagnin CM; Arns B; Vieceli T; Pereira DC; Lutz L; de Souza ÂC; Dos Santos JN; Guerra RR; Medeiros GS; Santoro L; Falci DR; Rigatto MH; Barth AL; Martins AF; Zavascki AP
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.
    Tumbarello M; Trecarichi EM; Corona A; De Rosa FG; Bassetti M; Mussini C; Menichetti F; Viscoli C; Campoli C; Venditti M; De Gasperi A; Mularoni A; Tascini C; Parruti G; Pallotto C; Sica S; Concia E; Cultrera R; De Pascale G; Capone A; Antinori S; Corcione S; Righi E; Losito AR; Digaetano M; Amadori F; Giacobbe DR; Ceccarelli G; Mazza E; Raffaelli F; Spanu T; Cauda R; Viale P
    Clin Infect Dis; 2019 Jan; 68(3):355-364. PubMed ID: 29893802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.